Successful second-line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal-epithelial transition factor amplification.
c-Met
cabozantinib
comprehensive genetic profiling test
hepatocellular carcinoma
second-line therapy
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
10 Oct 2023
10 Oct 2023
Historique:
revised:
27
09
2023
received:
01
06
2023
accepted:
08
10
2023
pubmed:
11
10
2023
medline:
11
10
2023
entrez:
11
10
2023
Statut:
aheadofprint
Résumé
A 72-year-old man with metastatic hepatocellular carcinoma previously received first-line systemic therapy with atezolizumab plus bevacizumab. His disease was judged to be progressing 5 months after treatment initiation. Comprehensive genomic profiling revealed cytoplasmic mesenchymal-epithelial transition factor amplification. On the basis of an expert panel's recommendation, he received cabozantinib as second-line therapy. The tumors shrank markedly and continued to shrink 6 months after treatment. Comprehensive genomic profiling could provide useful information for selecting effective second-line treatments for patients with hepatocellular carcinoma after first-line immunotherapy.
Types de publication
Case Reports
Langues
eng
Informations de copyright
© 2023 Japan Society of Hepatology.
Références
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-1905. https://doi.org/10.1056/NEJMoa1915745
Ghassan K, Abou-Alfa GK, Lau G, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. N Engl J Med. 2022;1(8). https://doi.org/10.1056/EVIDoa2100070
Sri HT, Anuhya K, Borad MJ, Mahipal A. Second-line therapies in advanced biliary tract cancers. Lancet Oncol. 2020;21(1):e29-e41. https://doi.org/10.1016/S1470-2045(19)30733-8
Giuseppe L, Elisa A, Monia S, Rizzo A, Parisi C, Di Federico A, et al. Beyond EGFR, ALK and ROS1: current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. Crit Rev Oncol Hematol. 2020;156:103119. https://doi.org/10.1016/j.critrevonc.2020.103119
Terashima T, Yamashita T, Takata N, Toyama T, Shimakami T, Takatori H, et al. Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma. Hepatol Res. 2020;50(7):871-884. https://doi.org/10.1111/hepr.13505
Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJ, et al. Capmatinib in MET exon 14-mutated or MET amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944-957. https://doi.org/10.1056/NEJMoa2002787
Shukui Q, Stephen LC, Wattana S, Guohong H , Su PC, Virote S, et al. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2019;11. https://doi.org/10.1177/1758835919889001
Lorenza R, Eric A, Markus PR, Marc P, Vittorina Z, Philippe M, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomized placebo-controlled study. Lancet Oncol. 2018;19(5):682-693. https://doi.org/10.1016/S1470-2045(18)30146-3
Robin KK, Lorenza R, Ann-Lin C, Ahmed K, Shukui Q, Andrew XZ, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC−312): a muliticentre, open-label, randomized, phase 3 trial. Lancet Oncol. 2022;23(8):995-1008. https://doi.org/10.1016/S1470-2045(22)00326-6
Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3(19):e59125. https://doi.org/10.1172/jci.insight.59125
Sang BY, Kim G, Hwang S, Kang H, Chon HJ. Dramatic response to cabozantinib in a patient with refractory hepatocellular carcinoma with c-MET amplification. J Clin Transl Hepatol. 2023;11(3):747-750. https://doi.org/10.14218/JCTH.2022.00212
Kondo S, Ojima H, Tsuda H, Hashimoto J, Morizane C, Ikeda M, et al. Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. J Clin Oncol. 2013;18(2):207-213. https://doi.org/10.1007/s10147-011-0361-9
Tomonari T, Tani J, Ogawa C, Deguchi A, Senoh T, Moriya A, et al. Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma. Hepatol Res. 2022;53(2):172-178. https://doi.org/10.1111/hepr.13845